| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
The major limiting factor in the successful application of adjuvant therapy for metastatic disease is the lack of adjuvant specificity that leads to severe side effects. Reasoning that T cells of the immune system are highly specific, we generated tumor-specific T cells by genetic modification of mouse primary T cells with a chimeric receptor reactive with the human breast cancer-associated Ag erbB-2. These T cells killed breast cancer cells and secreted IFN-
in an Ag-specific manner in vitro. We investigated their use against metastatic breast cancer in mice in an adjuvant setting, and compared their effectiveness with the commonly applied adjuvants doxorubicin, 5-fluorouracil, and herceptin. Mice were inoculated orthotopically with the human erbB-2-expressing spontaneously metastatic mouse breast cancer 4T1.2 in mammary tissue, and the primary tumor was surgically removed 8 days later. Significant metastatic disease was demonstrated in lung and liver at the time of surgery on day 8 with increased tumor burden at later time points. T cell adjuvant treatment of day 8 metastatic disease resulted in dramatic increases in survival of mice, and this survival was significantly greater than that afforded by either doxorubicin, 5-fluorouracil, or herceptin.
This article has been cited by other articles:
|
|
 |
|
  Y. Zhao, Q. J. Wang, S. Yang, J. N. Kochenderfer, Z. Zheng, X. Zhong, M. Sadelain, Z. Eshhar, S. A. Rosenberg, and R. A. Morgan A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity J. Immunol., November 1, 2009; 183(9): 5563 - 5574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. L. Teng, J. Sharkey, N. M. McLaughlin, M. A. Exley, and M. J. Smyth CD1d-Based Combination Therapy Eradicates Established Tumors in Mice J. Immunol., August 1, 2009; 183(3): 1911 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Till, M. C. Jensen, J. Wang, E. Y. Chen, B. L. Wood, H. A. Greisman, X. Qian, S. E. James, A. Raubitschek, S. J. Forman, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Blood, September 15, 2008; 112(6): 2261 - 2271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Pegram, J. T. Jackson, M. J. Smyth, M. H. Kershaw, and P. K. Darcy Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo J. Immunol., September 1, 2008; 181(5): 3449 - 3455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-R. Jiang, D. E. Gilham, K. Mulryan, N. Kirillova, R. E. Hawkins, and P. L. Stern Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors J. Immunol., October 1, 2006; 177(7): 4288 - 4298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Duval, H. Schmidt, K. Kaltoft, K. Fode, J. J. Jensen, S. M. Sorensen, M. I. Nishimura, and H. von der Maase Adoptive Transfer of Allogeneic Cytotoxic T Lymphocytes Equipped with a HLA-A2 Restricted MART-1 T-Cell Receptor: A Phase I Trial in Metastatic Melanoma Clin. Cancer Res., February 15, 2006; 12(4): 1229 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Moeller, N. M. Haynes, M. H. Kershaw, J. T. Jackson, M. W. L. Teng, S. E. Street, L. Cerutti, S. M. Jane, J. A. Trapani, M. J. Smyth, et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection Blood, November 1, 2005; 106(9): 2995 - 3003. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
